Latest News for: sosei

Edit

Issuer's Early Redemption (Call Option)::Mandatory (Sosei Group Corporation)

Public Technologies 19 Aug 2021
Sosei Group Corporation ... Sosei Group Corporation (the "Company") hereby gives notice to the holders of the outstanding ¥16,000,000,000 0.5% Convertible Bonds due 2025 (ISIN ... This notice is given by Sosei Group Corporation 19 August 2021 ... Sosei Group Corporation published ...
Edit

Quarterly Report for the Second Quarter of 2021 (Quarter ended June 30, 2021) (Sosei Group Corporation)

Public Technologies 13 Aug 2021
Sosei Group Corporation ... Sosei Group Corporation makes no warranty of any nature as to the accuracy of this English translation and assumes no responsibility for this translation or for direct, indirect or any other form of damages arising from the translation ... Sosei Group Corporation ... Sosei Group Corporation ... Sosei Group Corporation.
Edit

Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021 (Sosei Group Corporation)

Public Technologies 12 Aug 2021
Tokyo, Japan and Cambridge, UK, 12 August 2021 - Sosei Group Corporation ('the Company'; TSE ... Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented ... Sosei Group Corporation published this content on 12 August 2021 and is solely responsible for the information contained therein.
Edit

H1 FY2021 Financial Results Presentation (Sosei Group Corporation)

Public Technologies 12 Aug 2021
Sosei Group Corporation (TSE.4565) ... The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the "Company") as of the date of this presentation ... © Sosei Group Corporation. Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation.
Edit

Financial Statements and Related Announcement::Second Quarter and/ or Half Yearly Results (Sosei Group Corporation)

Public Technologies 12 Aug 2021
). Consolidated Financial Results for the Six Month Period Ended June 30, 2021 (IFRS). August 12, 2021 ... Sosei Group Corporation. Listing ... URL ... Achievement of this milestone triggered a payment of US$5 million to Sosei Heptares ... Sosei Group Corporation published this content on 12 August 2021 and is solely responsible for the information contained therein.
Edit

Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021

PR Newswire 12 Aug 2021
12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE ... Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented ... About Sosei Heptares ... Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK ... SOURCE Sosei Heptares.
Edit

Sosei Announces Determination of the Issuance Terms for its Convertible Bonds (Sosei Group Corporation)

Public Technologies 07 Jul 2021
Sosei Announces Determination of the Issuance Terms for its Convertible Bonds. Tokyo, Japan and Cambridge, UK, 7 July 2021 - Sosei Group Corporation ("Sosei"; TSE Mothers Index ... Sosei has determined that it will repurchase ¥15,750,000,000 in aggregate principal amount of the outstanding ¥16,000,000,000 0.5% Convertible Bonds due 2025 (ISIN.
Edit

Sosei Announces Issuance of Convertible Bonds and Buyback of Existing Convertible Bonds (Sosei Group Corporation)

Public Technologies 07 Jul 2021
Sosei Announces Issuance of Convertible Bonds and Buyback of Existing Convertible Bonds. Tokyo, Japan, and Cambridge, UK, 7 July 2021 - Sosei Group Corporation ("Sosei"; TSE Mothers Index ... The Stock Acquisition Rights are exercisable for shares of common stock of Sosei ... About Sosei Heptares.
Edit

Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery ...

Omaha World-Herald 06 Jul 2021
Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early development capabilitiesCollaboration to focus on identifying GPCR targets across multiple disease areas.
Edit

Sosei Heptares Initiates Phase 1 Trial with Novel Small-Molecule CGRP Antagonist under Collaboration with Biohaven (Sosei Group Corporation)

Public Technologies 23 Jun 2021
Tokyo, Japan and Cambridge, UK, 23 June 2021 - Sosei Group Corporation ("the Company"; TSE ... HTL0022562 (also known as BHV3100) is a novel, small molecule CGRP* receptor antagonist discovered by Sosei Heptares and the lead compound in a portfolio of CGRP antagonists licensed to Biohaven Pharmaceutical Holding Company Ltd.
×